IRVINE, Calif., May 20, 2005 (PRIMEZONE) -- An informational report on a biotech company developing technology to increase the safety and effectiveness of drug-coated cardiovascular stents has been made available free of charge to readers of SmallCap Sentinel. This news comes on the heels of a new announcement by MIV Therapeutics, Inc. (OTCBB:MIVT) detailing the expansion of the company's intellectual property portfolio of next-generation biocompatible medical device coatings.
"MIV Therapeutics products are designed to greatly reduce the inflammation issues associated with many medical devices," stated SmallCap Sentinel analyst D.R. Clark. "Today's announcement by MIV Therapeutics would seem to indicate the company's focus on creating a suite of devices in this field. In essence, they've sewn up a pipeline for new technology in this arena."
Other stent-related public companies include Angiotech Pharmaceuticals Inc. (Nasdaq:ANPI), Conor Medsystems Inc. (Nasdaq:CONR), and Guidant Corp. (NYSE:GDT).
Today's news follows the recent publication of results of a research study in one of the nation's most respected medical journals, which examined the performance of drug-coated stents in cardiovascular disease patients. Stents are expandable wire-mesh devices placed in clogged blood vessels to prop open the vessels to maintain healthy blood flow to the heart or elsewhere in the body. The study, recently reported in the Journal of the American Medical Association (JAMA), confirmed findings of prior research indicating that commonly used drug-coated stents cause a much higher rate of complications and death than previously thought. The report further validates the importance of research by stent technology companies toward creation of improved technology, in particular the need for stents that demonstrate improved biocompatibility. Interested parties may view information about MIVT free of charge via this direct link: http://www.trilogy-capital.com/tcp/mivt/factsheet.html
Forward-Looking Statements
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that will affect the results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project its capabilities, intent, resources, or experience.
The information, opinions and analysis contained herein are based on sources believed to be reliable but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement and is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid fifteen hundred dollars by MIV Therapeutics Corp for preparation and distribution of this report and other advertising services. This release has been approved by the company or its representatives. Additionally, MP and/or its affiliates, associates and employees from time to time may have either a long or short position in any securities mentioned. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.